Enantis has entered into a global supply agreement with one of the top providers of life science solutions with our innovative FGF10-STAB®. This novel, engineered protein protected by a patent is now entering the research and cell therapy market.

This is the second global supply agreement Enantis has in place. The first one covers the distribution of FGF2-STAB® molecule and we hope the new contract will bring similar business success.

Under the terms of agreement, Enantis will exclusively supply the laboratory reagents provider with FGF10-STAB® to assure worldwide accessibility of this molecule to the scientific community.